2021 Annual Report cover

IBRI 2021 Annual Report “Accelerating Biomedical Innovation”

read the report

Lilly Diabetes Center of Excellence at the IBRI

Translating disease research into new therapies

Scientists using centrifuge
Pipettes sitting in lab

What We Do

The Lilly Diabetes Center of Excellence (DCOE) at the Indiana Biosciences Research Institute (IBRI), which is a collaboration among Eli Lilly and Company, the IBRI and the Indiana University School of Medicine, is poised to innovate in diabetes care through its research into the pathogenesis of type 1 and type 2 diabetes.

Specifically, IBRI researchers are pursuing cutting-edge research into how the brain effects energy expenditure and metabolism through the neuroendocrine axis, and the role of the immune system on beta cell function. The goal of these integrated research lines, tackling the different pathways that lead to obesity and diabetes, is to improve the lives of individuals with diabetes and ultimately lead to diabetes prevention.

The labs that are part of the Lilly DCOE include:


Robert Considine, PhD
Administrative Director